

Interaction Report

Report ID:
Date Produced: 03 May 2024

Hepatology Treatment**Co-medications**

Glecaprevir/Pibrentasvir
Sofosbuvir/Velpatasvir

Methotrexate

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown. Please note that some co-medications with a green classification may require dose adjustment due to hepatic impairment.

For full details of all interactions, see www.hepatology-druginteractions.org.

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Sofosbuvir/Velpatasvir + Methotrexate

Coadministration has not been studied. Methotrexate is a substrate of BCRP and concentrations may increase due to inhibition by sofosbuvir/velpatasvir. Although no a priori dose alteration is required, close monitoring is recommended.

Glecaprevir/Pibrentasvir + Methotrexate

Coadministration has not been studied. Methotrexate is a substrate of BCRP and concentrations could increase due to inhibition of BCRP by glecaprevir/pibrentasvir. Patients should be closely monitored for methotrexate associated toxicities.